Steven AR Murphy: The Risk of Pulmonary Embolism in IV Stem Cell Therapy
Steven AR Murphy, Medical Director at Concierge Medical Associates, reposted from World Mitochondria Society on LinkedIn:
“IV infusion of mesenchymal stem cells resulting in mitochondrial aggregation and pulmonary embolism! That is the risk of IV stem cell therapy. World Mitochondria Society highlights this REAL risk. Concierge Medical Associates and I work with teams all over the globe to educate about the potential of mitochondrial transfer and about the risks of PE from these therapies. I’m so glad the science is being presented in Germany! We need a meeting in the USA now before we see some seriously Wild West risks and poor outcomes! p.s. that autologous MSC or PRP you received, that’s a mitochondrial transfer….”
Quoting World Mitochondria Society‘s post:
“Development of Mitochondria-Based Therapeutic Strategies for Disease Treatment. Prof. Kosuke Kusamori (Tokyo University of Science, Japan) presented innovative research advancing the field of mitochondrial transplantation and organelle-based therapy. His team investigated the use of mitochondria isolated from mesenchymal stromal cells (C3H10T1/2) as bioenergetic therapeutics capable of restoring damaged tissues. These mitochondria demonstrated strong antioxidant, proliferative, and cytoprotective properties, particularly in models of acute liver injury.
However, Prof. Kusamori identified a critical barrier to clinical translation: mitochondrial aggregation following systemic administration, which can cause pulmonary embolism. His group developed a proprietary anti-aggregation modification, allowing for safe intravenous delivery, targeted accumulation in the liver, and significant reduction of hepatic injury markers (ALT, AST).
This breakthrough demonstrates that controlling the physicochemical properties of isolated mitochondria is essential to unlock their therapeutic potential, a decisive step toward safe and effective mitochondria-based treatments for inflammatory and ischemic diseases.
Thanks for these excellent study.”
Stay updated with Hemostasis Today.
-
Dec 19, 2025, 13:30PPTA Europe’s Holiday Message: Wishing Health, Rest, and Renewal for 2026
-
Dec 19, 2025, 13:22If You Were Reading a “Bible for Blood Donation Volunteers,” What’s the ONE Thing That Must Be in It?
-
Dec 19, 2025, 12:52Julia Owens: Stroke Remains One of the World’s Leading Causes of Death and Disability
-
Dec 19, 2025, 12:03Pradeep Natarajan: Our New Genetic Study of Aortic Stenosis in ~3M
-
Dec 19, 2025, 11:47ESO Blog: Anna Gardin on Stroke Risk in the Era of Climate Extremes
-
Dec 19, 2025, 10:51Sarah Elkourashy Presents Insights on Caplacizumab for TTP at ASH25
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025